

## MDM2 (Phospho Tyr394) Antibody

Catalog No: YP1210

**Reactivity:** Human; Mouse

**Applications:** WB;ELISA

Target: MDM2

**Fields:** >>Endocrine resistance;>>Platinum drug resistance;>>FoxO signaling

pathway;>>Cell cycle;>>p53 signaling pathway;>>Ubiquitin mediated proteolysis;>>Endocytosis;>>PI3K-Akt signaling pathway;>>Cellular

senescence;>>C-type lectin receptor signaling pathway;>>Thyroid hormone signaling pathway;>>Shigellosis;>>Human cytomegalovirus infection;>>Human

papillomavirus infection;>>Epstein-Barr virus infection;>>Pathways in

cancer;>>Transcriptional misregulation in cancer;>>Viral carcinogenesis;>>Proteoglycans in cancer;>>MicroRNAs in

cancer;>>Glioma;>>Prostate cancer;>>Melanoma;>>Bladder cancer;>>Chronic

myeloid leukemia

Gene Name: MDM2

**Protein Name:** E3 ubiquitin-protein ligase Mdm2 (EC 6.3.2.-) (Double minute 2 protein) (Hdm2)

(Oncoprotein Mdm2) (p53-binding protein Mdm2)

Human Gene Id: 4193

Human Swiss Prot Q00987

No:

Mouse Swiss Prot P23804

No:

Immunogen: Synthesized phospho-peptide around the phosphorylation site of human MDM2

(Phospho-Tyr394)

**Specificity:** The antibody detects endogenous MDM2 (Phospho-Tyr394) Antibody

**Formulation :** Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Source: Polyclonal, Rabbit, lgG

1/3



WB 1:500-2000, ELISA 1:10000-20000 **Dilution:** 

**Purification:** The antibody was affinity-purified from rabbit antiserum by affinity-

chromatography using epitope-specific immunogen.

Concentration: 1 mg/ml

**Storage Stability:** -15°C to -25°C/1 year(Do not lower than -25°C)

**Observed Band:** 42kD

**Cell Pathway:** Cell Cycle G1S;Cell Cycle G2M DNA;p53;Ubiquitin mediated

> proteolysis; Endocytosis; Pathways in cancer; Glioma; Prostate cancer;Melanoma;Bladder cancer;Chronic myeloid leukemia;

**Background:** This gene encodes a nuclear-localized E3 ubiquitin ligase. The encoded protein

can promote tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. This gene is itself transcriptionally-regulated by p53. Overexpression or amplification of this locus is detected in a variety of different cancers. There is a pseudogene for this gene on chromosome 2.

Alternative splicing results in a multitude of transcript variants, many of which may

be expressed only in tumor cells. [provided by RefSeq, Jun 2013],

**Function:** disease: Seems to be amplified in certain tumors (including soft tissue sarcomas,

osteosarcomas and gliomas). A higher frequency of splice variants lacking p53 binding domain sequences was found in late-stage and high-grade ovarian and

bladder carcinomas. Four of the splice variants show loss of p53

binding.,domain:Region I is sufficient for binding p53 and inhibiting its G1 arrest and apoptosis functions. It also binds p73 and E2F1. Region II contains most of a central acidic region required for interaction with ribosomal protein L5 and a putative C4-type zinc finger. The RING finger domain which coordinates two molecules of zinc interacts specifically with RNA whether or not zinc is present and mediates the heterooligomerization with MDM4. It is also essential for its ubiquitin ligase E3 activity toward p53 and itself., function: Inhibits TP53/p53- and

TP73/p73-mediated cell cycle arrest

Subcellular Location:

Nucleus, nucleoplasm. Cytoplasm. Nucleus, nucleolus. Nucleus . Expressed predominantly in the nucleoplasm. Interaction with ARF(P14) results in the localization of both proteins to the nucleolus. The nucleolar localization signals in both ARF(P14) and MDM2 may be necessary to allow efficient nucleolar

localization of both proteins. Colocalizes with RASSF1 isoform A in the nucleus.

Ubiquitous. Isoform Mdm2-A, isoform Mdm2-B, isoform Mdm2-C, isoform **Expression:** 

Mdm2-D, isoform Mdm2-E, isoform Mdm2-F and isoform Mdm2-G are observed

in a range of cancers but absent in normal tissues.



## **Products Images**

Western blot analysis of HELA-UV Cell Lysate using antibody

